|
|
Blood, 1 April 2006, Vol. 107, No. 7, pp. 2839-2845.
Prepublished online as a Blood First Edition Paper on December 20, 2005; DOI 10.1182/blood-2005-08-3325.
 Previous Article | Next Article 
Submitted August 16, 2005
Accepted November 22, 2005
Identifying a common molecular mechanism for inhibition of MITF and STAT3 by PIAS3
Carmit Levy, Yu Nee Lee, Hovav Nechushtan, Ora Schueler-Furman, Amir Sonnenblick, Shelly Hacohen, and Ehud Razin*
Biochemistry, Hebrew University Hadassah Medical School, Jerusalem, Israel
Oncology, Hadassah Hebrew University Medical Center, Jerusalem, Israel
Molecular Genetics and Biotechnology, Hebrew University Hadassah Medical School, Jerusalem, Israel
* Corresponding author; email: ehudr{at}md.huji.ac.il.
Protein inhibitor of activated STAT3 (PIAS3) functions in vivo as a key molecule in suppressing the transcriptional activity of both microphthalmia transcription factor (MITF) and signal transducer and activator of transcription 3 (STAT3), two transcription factors that play a major role in the regulation of growth and function in mast cells and melanocytes. Previously we have demonstrated binding of PIAS3 to MITF leading to the inhibition of MITF transcriptional activity. Following cellular activation, PIAS3 is released from MITF and binds to STAT3. Now we have localized a common binding motif in PIAS3 for MITF and STAT3. This motif (PIAS82-132), which contains 50 amino acids, is sufficient for the inhibition of both MITF and STAT3. Three-dimensional protein modeling demonstrated that this motif contains two alpha helices. Disruption of one of the helices led to the loss of PIAS3 inhibitory activity. In addition to contributing to our understanding of the mechanisms of PIAS3 activity, these results could pave the way towards the formulation of an anti-oncogenic agent for the inhibition of both STAT3 and MITF.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. Dabir, A. Kluge, and A. Dowlati
The Association and Nuclear Translocation of the PIAS3-STAT3 Complex Is Ligand and Time Dependent
Mol. Cancer Res.,
November 1, 2009;
7(11):
1854 - 1860.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hikata, H. Takaishi, J. Takito, A. Hakozaki, M. Furukawa, S. Uchikawa, T. Kimura, Y. Okada, M. Matsumoto, A. Yoshimura, et al.
PIAS3 negatively regulates RANKL-mediated osteoclastogenesis directly in osteoclast precursors and indirectly via osteoblasts
Blood,
March 5, 2009;
113(10):
2202 - 2212.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Z. Yagil, G. Kay, H. Nechushtan, and E. Razin
A Specific Epitope of Protein Inhibitor of Activated STAT3 Is Responsible for the Induction of Apoptosis in Rat Transformed Mast Cells
J. Immunol.,
February 15, 2009;
182(4):
2168 - 2175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Duechting, C. Tschope, H. Kaiser, T. Lamkemeyer, N. Tanaka, S. Aberle, F. Lang, J. Torresi, R. Kandolf, and C.-T. Bock
Human Parvovirus B19 NS1 Protein Modulates Inflammatory Signaling by Activation of STAT3/PIAS3 in Human Endothelial Cells
J. Virol.,
August 15, 2008;
82(16):
7942 - 7952.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J.-i. Kashiwakura, W. Xiao, J. Kitaura, Y. Kawakami, M. Maeda-Yamamoto, J. R. Pfeiffer, B. S. Wilson, U. Blank, and T. Kawakami
Pivotal Advance: IgE accelerates in vitro development of mast cells and modifies their phenotype
J. Leukoc. Biol.,
August 1, 2008;
84(2):
357 - 367.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
